01 November 2019
Visiongain has launched a new pharma report Dermatological Drugs Market Forecast 2020-2030: Psoriasis, Skin Infection, Acne, Dermatitis, Others.
The dermatological drugs market is a specialist segment of the pharmaceutical market which over the last several years has been growing at a faster rate than the overall market. This has been due partly to the high growth potential of biological treatments for psoriasis. The development of new antibacterial drugs to address the problems of population ageing and drug-resistant strains of bacteria will also contribute to the overall market growth. In other segments, high generic penetration and intense competition limit profitability.
The lead analyst of the report commented "The prevention and treatment of dermatological conditions is becoming a priority for many healthcare authorities worldwide. The increasing incidence of skin and skin structure infections (SSSI) acquired in hospitals and the community is being exacerbated by resistance to existing antibacterial therapies.
Moreover, the ageing immunocompromised population will drive the increasing prevalence of skin and skin structure infections. Throughout the forecast period, we expect global demand for dermatological drugs to increase significantly. This trend will be driven by the expansion in emerging markets, where expansion in healthcare provision will increase demand. Economic growth and the expansion of the middle class in these emerging markets will further drive the demand for dermatological treatments."
Leading companies featured in the report include AbbVie, Allergan, Amgen, Bausch Health, Bayer AG, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly, Galderma (Nestle Skin Health S.A.), GlaxoSmithKline (GSK) and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Increasing pollution in emerging economies has resulted in degradation of air quality which is one of the major reasons for increasing COPD and asthma prevalence amongst children and teenagers.
11 August 2020
Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry.
10 August 2020
Biosimilars will be changing the biologics market in the long term. But whether it does it for the better or the worse will depend on how the producers of biologics respond to their market presence.
06 August 2020
Conceptually, it is clear for all stakeholders in the health care segment as well in the biotechnological sector the benefits are evident since it will improve the speed and accuracy of diagnostics or analysis.